Exton, PA – According to filings with the U.S. Securities and Exchange Commission, Lungpacer Medical is raising $21,099,936.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Evans played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lungpacer Medical

Lungpacer Medical Inc. is developing a novel therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation. The proprietary Lungpacer system is designed to activate and exercise the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation catheter that is expected to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs. Lungpacer Medical, Inc., is a privately held medical device company focused on improving respiratory and critical care medicine. Headquartered in Vancouver, Canada, and with US offices in Exton, Pennsylvania, Lungpacer Medical is dedicated to designing non-surgical, minimally invasive technologies to ventilate patients more safely and effectively.

To learn more about Lungpacer Medical, visit http://lungpacer.com/

Contact:
Douglas Evans, Chief Executive Officer
778-655-2100
devans@lungpacer.com
https://www.linkedin.com/in/doug-evans-7a38126/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved